Fujii T - Search Results

1

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.

Kurozumi S, Yamaguchi Y, Matsumoto H, Inoue K, Kurosumi M, Oyama T, Horiguchi J, Fujii T, Shirabe K. Kurozumi S, et al. Among authors: fujii t. Med Mol Morphol. 2019 Jun;52(2):90-98. doi: 10.1007/s00795-018-0206-y. Epub 2018 Sep 27. Med Mol Morphol. 2019. PMID: 30259117

2

Implication of extracapsular invasion of sentinel lymph nodes in breast cancer: prediction of nonsentinel lymph node metastasis.

Fujii T, Yanagita Y, Fujisawa T, Hirakata T, Iijima M, Kuwano H. Fujii T, et al. World J Surg. 2010 Mar;34(3):544-8. doi: 10.1007/s00268-009-0389-4. World J Surg. 2010. PMID: 20066412

3

Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer.

Yamaki S, Fujii T, Yajima R, Hirakata T, Yamaguchi S, Fujisawa T, Tsutsumi S, Asao T, Yanagita Y, Iijima M, Kuwano H. Yamaki S, et al. Among authors: fujii t. Surg Today. 2013 Aug;43(8):901-5. doi: 10.1007/s00595-012-0378-3. Epub 2012 Oct 23. Surg Today. 2013. PMID: 23090139

4

Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.

Kato T, Fujii T, Ide M, Takada T, Sutoh T, Morita H, Yajima R, Yamaguchi S, Tsutsumi S, Asao T, Oyama T, Kuwano H. Kato T, et al. Among authors: fujii t. Anticancer Res. 2014 Jun;34(6):3141-6. Anticancer Res. 2014. PMID: 24922685

5

MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.

Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T, Kuwano H. Suto T, et al. Among authors: fujii t. Carcinogenesis. 2015 Mar;36(3):338-45. doi: 10.1093/carcin/bgu242. Epub 2014 Dec 10. Carcinogenesis. 2015. PMID: 25503932

6

Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.

Fujii T, Yajima R, Tsuboi M, Higuchi T, Obayashi S, Tokiniwa H, Nagaoka R, Takata D, Horiguchi J, Kuwano H. Fujii T, et al. Anticancer Res. 2016 Jun;36(6):3019-22. Anticancer Res. 2016. PMID: 27272820

7

Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.

Fujii T, Yajima R, Kurozumi S, Higuchi T, Obayashi S, Tokiniwa H, Nagaoka R, Takata D, Horiguchi J, Kuwano H. Fujii T, et al. Anticancer Res. 2016 Oct;36(10):5481-5485. doi: 10.21873/anticanres.11129. Anticancer Res. 2016. PMID: 27798919

8

Clinicopathological Features of Ductal Carcinoma In Situ from ¹⁸F-FDG-PET Findings.

Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Kuwano H. Fujii T, et al. Anticancer Res. 2017 Sep;37(9):5053-5056. doi: 10.21873/anticanres.11921. Anticancer Res. 2017. PMID: 28870933

9

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.

Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H. Kurozumi S, et al. Among authors: fujii t. Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21. Med Mol Morphol. 2017. PMID: 28936553 Review.

10

Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).

Fujii T, Horiguchi J, Yanagita Y, Koibuchi Y, Ikeda F, Uchida N, Kimura M; GUNMA BREAST CLINICAL CONFERENCE STUDY GROUP (GBCCSG). Fujii T, et al. Anticancer Res. 2018 Feb;38(2):905-909. doi: 10.21873/anticanres.12301. Anticancer Res. 2018. PMID: 29374719 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,544 results

Search Page

Filters